Lanean...
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine
BACKGROUND: The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as th...
Gorde:
| Argitaratua izan da: | Neurol Sci |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer International Publishing
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8223191/ https://ncbi.nlm.nih.gov/pubmed/34165650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10072-021-05409-6 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|